1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Women's Health - Pipeline Review, H2 2013

Women's Health - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 50 pages

Women's Health - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Women's Health - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Women's Health, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women's Health. Women's Health - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Women's Health.
- A review of the Women's Health products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Women's Health pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Women's Health.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Women's Health pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Women's Health - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Women's Health Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Women's Health 8
Women's Health Therapeutics under Development by Companies 10
Women's Health Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Women's Health Therapeutics - Products under Development by Companies 16
Women's Health Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Women's Health Therapeutics Development 18
GlaxoSmithKline plc 18
Neurocrine Biosciences, Inc. 19
GeneScience Pharmaceuticals Co., Ltd. 20
Intra-Cellular Therapies, Inc. 21
Zylera Pharmaceuticals 22
Women's Health - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
epelsiban besylate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
cidofovir - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
leuprolide acetate - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
GnRH Antagonists - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ZYL-3177X - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
ZYL-65987 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
NT-100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Women's Health Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
EVE-112 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
EVE-106 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Progesterone Based Formulation For Preterm Birth - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Women's Health Therapeutics - Drug Profile Updates 41
Women's Health Therapeutics - Dormant Products 42
Women's Health - Product Development Milestones 43
Featured News and Press Releases 43
Aug 20, 2013: Florida Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures 43
Sep 07, 2011: Repros Reports Interim Data From Phase III Study Of Low Dose Oral Proellex 43
Jul 19, 2010: Gilead Sciences Announces Results From Clinical Trial Of Tenofovir Gel For Women's HIV Prevention 44
Jun 25, 2010: Merck Challenges Verdict in Federal FOSAMAX (alendronate sodium) Trial 45
Jun 07, 2010: Statement on FOSAMAX (alendronate sodium) Product Liability Trial in U.S. District Court 46
May 06, 2010: Swedish Orphan Biovitrum Presents First Positive Kiobrina Clinical Phase II Data 46
May 05, 2010: Merck Wins Second Federal FOSAMAX (alendronate sodium) Bellwether Trial 47
Nov 23, 2009: Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX (alendronate sodium) 47
Sep 11, 2009: Mistrial Declared in First Federal FOSAMAX Trial 48
Sep 10, 2009: Pantarhei Bioscience Has Organised A Symposium At This Congress Of The European Society Of Gynecology, Rome, Italy 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50



List of Tables

Number of Products Under Development for Women's Health, H2 2013 8
Products under Development for Women's Health - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
GlaxoSmithKline plc, H2 2013 18
Neurocrine Biosciences, Inc., H2 2013 19
GeneScience Pharmaceuticals Co., Ltd., H2 2013 20
Intra-Cellular Therapies, Inc., H2 2013 21
Zylera Pharmaceuticals, H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 28
Women's Health Therapeutics - Drug Profile Updates 41
Women's Health Therapeutics - Dormant Products 42



List of Figures

Number of Products under Development for Women's Health, H2 2013 8
Products under Development for Women's Health - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 11
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Assessment by Route of Administration, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Molecule Type, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 28



Companies Mentioned

GlaxoSmithKline plc
Neurocrine Biosciences, Inc.
GeneScience Pharmaceuticals Co., Ltd.
Intra-Cellular Therapies, Inc.
Zylera Pharmaceuticals

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Merck Consumer Healthcare Belgium NV SA in Consumer Health (Belgium)

Merck Consumer Healthcare Belgium NV SA in Consumer Health (Belgium)

  • $ 131
  • Company report
  • September 2016
  • by Euromonitor International

The priority for Merck Consumer Healthcare Belgium, the leader in vitamins and dietary supplements in 2016, is expected to be to become more selective in its areas of investment in Belgium. Euromonito ...

Vita Green Health Products Co Ltd in Consumer Health (Hong Kong, China)

Vita Green Health Products Co Ltd in Consumer Health (Hong Kong, China)

  • $ 131
  • Company report
  • October 2016
  • by Euromonitor International

Vita Green Health Products is expected to focus on product innovation within dietary supplements in order to ensure that it is able to meet the evolving needs of consumers in Hong Kong. Euromonitor International ...

Nu Skin Enterprises HK Inc in Consumer Health (Hong Kong, China)

Nu Skin Enterprises HK Inc in Consumer Health (Hong Kong, China)

  • $ 131
  • Company report
  • October 2016
  • by Euromonitor International

Nu Skin Enterprises HK is expected to take advantage of rising health-consciousness amongst consumers in Hong Kong, and focus on product innovation in nutritional supplements during the forecast period. ...


Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Dietary Supplement

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.